GlassScriptPhysician profile
Rohit Chander Chopra
NPI 1750818936
$1,031.13
in general payments reported to CMS, 2019-2025
14 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.74 · 2021: $92.83 · 2022: $208 · 2023: $142 · 2024: $84.07 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $276.43 | 2024-2025 | Assure Wcd |
| Genzyme Corporation | $120.82 | 2025 | |
| Ardelyx, INC. | $119.61 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $105.14 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $69.73 | 2022 | |
| Merck Sharp & Dohme LLC | $61.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $57.80 | 2022 | |
| Abiomed | $54.48 | 2025 | |
| Abbott Laboratories | $44.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.53 | 2023 | Jardiance |
| Gilead Sciences, INC. | $29.78 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $27.71 | 2021 | |
| Boston Scientific Corporation | $16.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.39 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.